Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PurposeThis analysis evaluated patient-reported outcomes and analgesic use in patients with bone metastases from solid tumours across three comparative studies of denosumab and zoledronic acid.MethodsPooled data were analysed from three identically designed double-blind phase III studies comparing subcutaneous denosumab 120 mg with intravenous zoledronic acid 4 mg monthly in patients with bone metastases from breast cancer (n = 2,046), castration-resistant prostate cancer (n = 1,901) or other solid tumours (n = 1,597). Pain severity, pain interference, health-related quality of life and analgesic use were quantified.ResultsAt baseline, approximately half of patients had no/mild pain (53 % [1,386/2,620] denosumab; 50 % [1,297/2,578] zoledronic acid). Denosumab delayed onset of moderate/severe pain by 1.8 months (median, 6.5 vs 4.7 months; hazard ratio, 0.83; 95 % CI, 0.76–0.92; p < 0.001; 17 % risk reduction) and clinically meaningful increases in overall pain interference by 2.6 months (median, 10.3 vs 7.7 months; hazard ratio, 0.83; 95 % CI, 0.75–0.92; p < 0.001; 17 % risk reduction) compared with zoledronic acid. Strong opioid use and worsening of health-related quality of life were less common with denosumab.ConclusionsAcross three large studies of patients with advanced solid tumours and bone metastases, denosumab prevented progression of pain severity and pain interference more effectively than zoledronic acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020 · cited 11×
“Patient-reported outcomes (pain severity, pain interference with activity and affect and HRQoL) and analgesic use were assessed at monthly visits.”
MethodInfluentialBrucker, P. S., Yost, K., Cashy, J., Webster, K., & Cella, D. (2005) · Evaluation & the Health Professions · doi:10.1177/0163278705275341 · Cited by 528 · cited 11×
“Patient-reported outcomes (pain severity, pain interference with activity and affect and HRQoL) and analgesic use were assessed at monthly visits.”
ResultInfluential
Cited by
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
Smith, M. R., Coleman, R. E., Klotz, L., Pittman, K., Milecki, P., Ng, S., Chi, K. N., Balakumaran, A., Wei, R., Wang, H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu519 · Cited by 145
Self-citationCleeland, C., von Moos, R., Walker, M. S., Wang, Y., Gao, J., Chavez-MacGregor, M., Liede, A., Arellano, J., Balakumaran, A., & Qian, Y. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3154-x · Cited by 41
Self-citationBody, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3697-5 · Cited by 11
“tient HRQoL and strong opioid use were less common with denosumab than with zoledronic acid treatment [28].”
BackgroundSelf-citation
Metadata
- Authors
- von Moos, R., Body, J.-J., Egerdie, B., Stopeck, A., Brown, J. E., Damyanov, D., Fallowfield, L. J., Marx, G., Cleeland, C. S., Patrick, D. L., Palazzo, F. G., Qian, Y., Braun, A., & Chung, K.
- Venue
- Supportive Care in Cancer
- Published
- 2013-08-22
- Volume
- 21
- Issue
- 12
- Pages
- 3497-3507
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2039962951
- Cited by
- 95
- References
- 2
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.